沙库巴曲缬沙坦对心衰患者血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平的影响研究  

The study of influence of sacubitril/valsartan on plasma NE,AngⅡ,ALD and serum sCD40L,sICAM-1,sFas,sFasL and cTnI,MMP-9 levels in patients with heart failure

作　　者：李彦芬 陈春红[2] 王占起 王芳[2] 李雅[2] LI Yan-fen;CHEN Chun-hong;WANG Zhan-qi;WANG Fang;LI Ya(Department of Medicine, Baoding Hengtian Hospital, Hebei, Baoding 071000, China;Department of Cardiology, Affiliated Hospital of Hebei University, Hebei, Baoding 071000, China)

机构地区：[1]保定市恒天医院内科 [2]保定市河北大学附属医院心内科,河北保定071000

出　　处：《海南医学院学报》2018年第6期665-668,672,共5页Journal of Hainan Medical University

基　　金：河北省自然科学基金资助项目(H2016102348)~~

摘　　要：目的:研究沙库巴曲缬沙坦对心衰患者血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平的影响。方法:选取我院诊治的42例慢性心衰患者作为研究组,以及42例慢性心衰患者作为对照组。对照组在一般治疗的基础上加用80mg缬沙坦口服,每天1次,研究组患者在一般治疗的基础上加用50mg沙库巴曲缬沙坦口服,每天2次。比较两组治疗前后血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平。结果:治疗前,两组患者血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平之间均不存在统计学差异(P>0.05);(1)治疗后,两组血浆NE、AngⅡ、ALD水平与同组治疗前相比存在显著性差异(P<0.05),且两组之间也存在显著性差异(P<0.05);(2)治疗后,两组血清sCD40L、sICAM-1、sFas、sFasL水平与同组治疗前相比存在显著性差异(P<0.05),且两组之间也存在显著性差异(P<0.05);(3)治疗后,两组血清cTnI、MMP-9水平与同组治疗前相比存在显著性差异(P<0.05),且两组之间也存在显著性差异(P<0.05)。结论:对心衰患者在一般治疗的基础上应用沙库巴曲缬沙坦,不仅可以明显改善患者的血浆NE、AngⅡ、ALD水平,而且可以显著改善患者血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平,疗效更加显著,值得临床上研究应用。Objective： To study the influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure. Methods： To choose 42 cases of chronic heart failure in our hospital form August 2017 to December 2017 as the study group, and 42 cases of chronic heart failure form January 2017 to June 2017 as the control group. The patients in the control group were treated with 80mg valsartan on the basis of general treatment, 1 times a day, and the patients in the study group were added with 50mg sacubitril/valsartan on the basis of general treatment, 2 times a day. To compare the plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels before and after treatment in the two groups. Results： Before treatment, there was no statistical difference between the levels of plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 in the two groups（ P 〉0.05）; （1） After treatment, the levels of plasma NE, AngⅡ, ALD in the control group were （1959.43±294.67） pmol/L, （118.67±16.31） ng/L, （318.67±78.54） pg/mL, and the study group were （1712.35±234.88） pmol/L, （110.78±15.83） ng/L, （301.34±66.36） pg/mL, compared with those before treatment in the seme group, there were significant differences（ P 〈0.05）,and there were significant differences between the two groups（ P 〈0.05）; （2） After treatment, the levels of serum sCD40L, sICAM-1, sFas, sFasL in the control group were （13.45±1.58） ng/mL, （526.78±147.29） μg/L, （1.52± 0.42） ng/mL, （51.61±12.78） pg/mL, and the study group were （7.60±1.43） ng/mL, （433.95±117.56） μg/L, （1.17±0.21） ng/mL, （48.23±10.12） pg/mL, compared with those before treatment in the seme group, there were significant differences（ P 〈0.05）,and there were significant differences between the two groups（ P 〈0.05）; （3） After treatment, the levels of serum cTnI, MMP-9 in the control group w

关 键 词：心衰 沙库巴曲缬沙坦 血浆因子 血清因子 

分 类 号：R541[医药卫生—心血管疾病]